PMID- 37563417
OWN - NLM
STAT- Publisher
LR  - 20231021
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 15
DP  - 2023 Nov
TI  - Efficacy and safety of transarterial chemoembolization plus lenvatinib with or 
      without programmed death-1 inhibitors in the treatment of unresectable 
      hepatocellular carcinoma: a systematic review and meta-analysis.
PG  - 14451-14461
LID - 10.1007/s00432-023-05231-x [doi]
AB  - BACKGROUND: Programmed death-1 inhibitors plus lenvatinib and transarterial 
      chemoembolization (TACE) (P-L-T) is a novel combination strategy. This systematic 
      review and meta-analysis aimed to evaluate the efficacy and safety of P-L-T 
      compared with lenvatinib and TACE (L-T) therapy in patients with unresectable 
      hepatocellular carcinoma. METHODS: A systematic literature search of the PubMed, 
      Embase, Web of Science and Cochrane Library databases for studies investigating 
      P-L-T therapy was performed. Data regarding outcome data, including overall 
      survival (OS), progression-free survival (PFS), tumor response, and adverse 
      events (AEs), were independently extracted by two authors using a standardized 
      protocol. RESULTS: Eight cohort studies comprising 847 patients (P-L-T: 416, L-T: 
      431) were included in the meta-analysis. The P-L-T group exhibited significantly 
      longer OS (hazard ratio (Page et al.) 0.51 [95% confidence interval (CI) 
      0.42-0.62]; I(2) = 9.8%; p = 0.354] and PFS (HR 0.51 [95% CI 0.43-0.61]; 
      I(2) = 0%; p = 0.824), and higher objective response rate (risk ratio [RR] 1.54 
      [95% CI 1.33-1.78]; I(2) = 0%, p = 0.858]) and disease control rate (RR 1.27 [95% 
      CI 1.17-1.38]; I(2) = 17.3%; p = 0.467). Grade 3/4 AEs were more prevalent in the 
      P-L-T group, including hypertension (RR 1.91 [95% CI 1.16-3.15]), vomiting or 
      nausea (RR 2.29 [95% CI 1.01-5.19]), and hypothyroidism (RR 12.21 [95% CI 
      1.63-91.23]). CONCLUSION: Compared with L-T combination therapy, P-L-T 
      demonstrated a significant advantage in terms of OS, PFS, objective response 
      rate, disease control rate, and manageable AEs.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Liu, Junning
AU  - Liu J
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China.
FAU - Wei, Song
AU  - Wei S
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China.
FAU - Yang, Linfeng
AU  - Yang L
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China.
FAU - Yu, Jiahui
AU  - Yu J
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China.
FAU - Yan, Duan
AU  - Yan D
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China.
FAU - Yi, Pengsheng
AU  - Yi P
AD  - Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, 637000, China. liujunning98@163.com.
LA  - eng
GR  - 22SXQT0052/Bureau of Science and Technology Nanchong City/
PT  - Journal Article
PT  - Review
DEP - 20230811
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
SB  - IM
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Meta-analysis
OT  - Programmed death-1
OT  - Transarterial chemoembolization
EDAT- 2023/08/11 00:41
MHDA- 2023/08/11 00:41
CRDT- 2023/08/10 23:32
PHST- 2023/07/25 00:00 [received]
PHST- 2023/07/29 00:00 [accepted]
PHST- 2023/08/11 00:41 [pubmed]
PHST- 2023/08/11 00:41 [medline]
PHST- 2023/08/10 23:32 [entrez]
AID - 10.1007/s00432-023-05231-x [pii]
AID - 10.1007/s00432-023-05231-x [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Nov;149(15):14451-14461. doi: 
      10.1007/s00432-023-05231-x. Epub 2023 Aug 11.